In a significant development for ongoing pharmaceutical litigation, GSK Plc and Pfizer Inc. must face trials in state court in Delaware. This decision comes after Superior Court Judge Vivian Medinilla ruled that the evidence supporting claims their former heartburn medication, Zantac, causes cancer is credible enough to be presented to a jury. This ruling follows the dismissal of federal cases and arrives in the wake of a plaintiff’s loss in the first Zantac-related trial.
The litigation sees around 75,000 consumers filing suits in Delaware, collectively arguing that Zantac, which was owned by different companies over time, led to various types of cancer. Judge Medinilla found that the science underpinning these cancer claims is not flawed, allowing the disputes over experts’ analyses on these health risks to be properly debated in trial.
For more details on this development, you can read the full article here.